Barrios-Bernal, P.; Hernandez-Pedro, N.; Orozco-Morales, M.; Viedma-RodrÃguez, R.; Lucio-Lozada, J.; Avila-Moreno, F.; Cardona, A.F.; Rosell, R.; Arrieta, O.
Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells. Pharmaceuticals 2022, 15, 381.
https://doi.org/10.3390/ph15030381
AMA Style
Barrios-Bernal P, Hernandez-Pedro N, Orozco-Morales M, Viedma-RodrÃguez R, Lucio-Lozada J, Avila-Moreno F, Cardona AF, Rosell R, Arrieta O.
Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells. Pharmaceuticals. 2022; 15(3):381.
https://doi.org/10.3390/ph15030381
Chicago/Turabian Style
Barrios-Bernal, Pedro, Norma Hernandez-Pedro, Mario Orozco-Morales, Rubà Viedma-RodrÃguez, José Lucio-Lozada, Federico Avila-Moreno, Andrés F. Cardona, Rafael Rosell, and Oscar Arrieta.
2022. "Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells" Pharmaceuticals 15, no. 3: 381.
https://doi.org/10.3390/ph15030381
APA Style
Barrios-Bernal, P., Hernandez-Pedro, N., Orozco-Morales, M., Viedma-RodrÃguez, R., Lucio-Lozada, J., Avila-Moreno, F., Cardona, A. F., Rosell, R., & Arrieta, O.
(2022). Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial–Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells. Pharmaceuticals, 15(3), 381.
https://doi.org/10.3390/ph15030381